Skip to main content
SpringerLink
Log in

Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development

  • Chapter
Anticancer Drug Development Guide

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The use of animals for the preclinical study of cancer therapeutics has a long history, and important information has been gained regarding new and innovative therapies. Most of this work has been performed on inbred rodent models and laboratory-derived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally occurring tumors in people. Many of these concerns may be allayed through the study of naturally occurring tumors in our companion animal population, (i.e., dog and cat pet population). Companion animals with naturally occurring tumors, although presently underutilized, have and should continue to provide an excellent opportunity to investigate many aspects of malignancy from etiology to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reif JS, Bruns C, Lower KS. Cancer of the nasal cavity and paranasal sinuses and exposure to environmental tobacco smoke in pet dogs. Am J Epidemiol 1998; 147: 488 - 492.

    Article  PubMed  CAS  Google Scholar 

  2. Glickman LS, Shofer FS, McKee IJ. Epidemiologic study of insecticide exposure, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 1989; 28: 407 - 414.

    Article  PubMed  CAS  Google Scholar 

  3. Gavazza A, Presciuttini S, Barale R, Lubas G, Gugliucci B. Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. J Vet Intern Med 2001; 15: 190 - 195.

    Article  PubMed  CAS  Google Scholar 

  4. Hayes HM, Tarone RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC. Case-control study of canine malignant lymphoma: positive association with dog owner’s use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 1991; 83: 1226 - 1231.

    Article  PubMed  CAS  Google Scholar 

  5. Reif JS, Lower KS, Ogilvie GK. Residential exposure to magnetic fields and risk of canine lymphoma. Am J Epidemiol 1995; 141: 352 - 359.

    Article  PubMed  CAS  Google Scholar 

  6. Glickman LT, Domanski LM, Maguire TG, Dubielzig RR, Churg A. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environ Res 1983; 32: 305 - 313.

    Article  PubMed  CAS  Google Scholar 

  7. Dorn CR, Taylor DON, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968; 40: 307 - 318.

    PubMed  CAS  Google Scholar 

  8. Dorn CR. Epidemiology of canine and feline tumors. Comp Cont Ed Pract Vet 1976; 12: 307 - 312.

    Google Scholar 

  9. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl CancerinstMonogrNo. 54. Washington, DC: US Government Printing Office. 1980: 152.

    Google Scholar 

  10. LaRue SM, Fox MH, Withrow SJ, ddd, smdl. Impact of heterogeneity in the predictive value of kinetic parameters in canine osteosarcoma. Cancer Res 1994; 54: 3916 - 3921.

    PubMed  CAS  Google Scholar 

  11. Zeman EM, Calkins DP, Cline JM, Thrall DE. The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 1993; 27: 891 - 898.

    Article  PubMed  CAS  Google Scholar 

  12. Vail DM, Kisseberth WC, Obradovich JE, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin’s lymphoma. Exp Hematol 1996; 24: 807 - 815.

    PubMed  CAS  Google Scholar 

  13. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999; 5: 2653 - 2659.

    PubMed  CAS  Google Scholar 

  14. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol 2001; 19: 1839 - 1847.

    PubMed  CAS  Google Scholar 

  15. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000; 18: 781 - 792.

    Article  PubMed  CAS  Google Scholar 

  16. Bronson RT. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982; 43: 2057 - 2059.

    PubMed  CAS  Google Scholar 

  17. Teclaw R, Mendlein J, Garbe P, Mariolis P. Characteristics of pet populations and households in the Purdue Comparative Oncology Program catchment area. JAm Vet Med Assoc 1988; 201: 1725 - 1729.

    Google Scholar 

  18. Steplewski Z, Rosales C, Jeglum KA, McDonald-Smith J. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies. In Vivo 1990; 4: 231 - 234.

    PubMed  CAS  Google Scholar 

  19. Ghernati I, Auger C, Chabanne L, et al. Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sezary syndrome and producing retroviral particles. Leukemia 1999; 13: 1281 - 1290.

    Article  PubMed  CAS  Google Scholar 

  20. Nakaichi M, Taura Y, Kanki M, et al. Establishment and characterization of a new canine B-cell leukemia cell line. J Vet Med Sci 1996; 58: 469 - 471.

    Article  PubMed  CAS  Google Scholar 

  21. Thamm DH, Dickerson EB, Helfand SC, MacEwen EG. Expression of angiogenic growth factors and receptors in canine angiosarcoma. In: Proceedings of the American Association of Cancer Research, New Orleans, LA, 2001.

    Google Scholar 

  22. Shoieb AM, Hahn KA, Barnhill MA. An in vivo/in vitro experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998; 12: 463 - 472.

    PubMed  CAS  Google Scholar 

  23. Cakir Y, Hahn KA. Direct action by doxycycline against canine osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro. In Vivo 1999; 13: 327 - 331.

    PubMed  CAS  Google Scholar 

  24. Ahern TE, Bird RC, Bird AE, Wolfe LG. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 1996; 57: 693 - 696.

    PubMed  CAS  Google Scholar 

  25. Muleya JS, Nakaichi M, Sugahara J, Taura Y, Murata T, Nakama S. Establishment and characterization of a new cell line derived from feline mammary tumor. J Vet Med Sci 1998; 60: 931 - 935.

    Article  PubMed  CAS  Google Scholar 

  26. Hogge GS, Burkholder JK, Culp J, et al. Preclinical development of hGM-CSF transfected melanoma cell vaccines using established canine cell lines and normal canines. Cancer Gene Ther 1998; 6: 26 - 36.

    Article  CAS  Google Scholar 

  27. Ahern TE, Bird RC, Bird AE, Wolfe LG. Overexpression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines, is associated with metastatic potential in nude mice. Anticancer Res 1993; 13: 1365 - 1371.

    PubMed  CAS  Google Scholar 

  28. Koenig A, Wojcieszyn J, Weeks BR, Modiano JF. Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cell lines and twenty-nine retrospective cases of canine melanoma. Vet Pathol 2001; 38: 427 - 435.

    Article  PubMed  CAS  Google Scholar 

  29. Knapp DW, Chan TC, Kuczek T, Reagan WJ, Park B. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995; 56: 801 - 805.

    PubMed  CAS  Google Scholar 

  30. Tannehill-Gregg S, Kergosien E, Rosol TJ. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. In Vitro Cell Dey Biol Anim 2001; 37: 676 - 683.

    Article  CAS  Google Scholar 

  31. Katayama R, Huelsmeyer MK, Vail DM, Kurzman ID, MacEwen EG. Selective inhibition of platelet-derived growth factor receptor activity in feline vaccine-associated sarcoma. In: Proceedings of the American Association Cancer Research, San Francisco, April 6 - 10, 2002.

    Google Scholar 

  32. Ma Z, Khatlani TS, Li L, et al. Molecular cloning and expression analysis of feline melanoma antigen (MAGE) obtained from a lymphoma cell line. Vet Immunol Immunopathol 2001; 83: 241 - 252.

    CAS  Google Scholar 

  33. Okai Y, Nakamura N, Matsushiro H, et al. Molecular analysis of multidrug resistance in feline lymphoma cells. Am J Vet Res 2000; 61: 1122 - 1127.

    Article  PubMed  CAS  Google Scholar 

  34. Cline JM, Thrall DE, Page RL, et al. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br J Cancer 1990; 62: 925 - 931.

    Article  PubMed  CAS  Google Scholar 

  35. Cline JM, Thrall DE, Rosner GL, Raleigh JA. Distribution of the hypoxic marker CCI-103F in canine tumors. Int J Radiat Oncol Biol Phys 1994; 28: 921 - 933.

    Article  PubMed  CAS  Google Scholar 

  36. Raleigh JA, Zeman EM, Rathman M, et al. Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue. Int J Radial Oncol Biol Phys 1992; 22: 403 - 405.

    Article  CAS  Google Scholar 

  37. Raleigh JA, Zeman EM, Calkins DP, McEntee MC, Thrall DE. Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors. Acta Oncol 1995; 34: 345 - 349.

    Article  PubMed  CAS  Google Scholar 

  38. Thrall DE, McEntee MC, Cline JM, Raleigh JA. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation. Int J Radiat Oncol Biol Phys 1994; 28: 649 - 659.

    Article  PubMed  CAS  Google Scholar 

  39. Vujaskovic Z, Poulson JM, Gaskin AA, et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000; 46: 179 - 185.

    Article  PubMed  CAS  Google Scholar 

  40. Mathias CJ, Green MA, Morrison WB, Knapp DW. Evaluation of Cu-PTSM as a tracer of tumor perfusion: comparison with labeled microspheres in spontaneous canine neoplasms. Nucl Med Biol 1994; 21: 83 - 87.

    Article  PubMed  CAS  Google Scholar 

  41. Van Camp S, Fisher P, Thrall DE. Dynamic CT measurement of contrast medium washin kinetics in canine nasal tumors. Vet Radiol Ultrasound 2000; 41: 403 - 408.

    Article  PubMed  Google Scholar 

  42. Rocha TA, Mauldin GN, Patnaik AK, Bergman PJ. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000; 14: 486 - 490.

    Article  PubMed  CAS  Google Scholar 

  43. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002; 62: 356 - 358.

    PubMed  CAS  Google Scholar 

  44. Coomber BL, Denton J, Sylvestre A, Kruth S. Blood vessel density in canine osteosarcoma. Can J Vet Res 1998; 62: 199 - 204.

    PubMed  CAS  Google Scholar 

  45. Gonzalez CM, Griffey SM, Naydan DK, et al. Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy. J Comp Pathol 2000; 122: 241 - 248.

    Article  PubMed  CAS  Google Scholar 

  46. Griffey SM, Verstraete FJ, Kraegel SA, Lucroy MD, Madewell BR. Computer-assisted image analysis of intratumoral vessel density in mammary tumors from dogs. Am J Vet Res 1998; 59: 1238 - 1242.

    PubMed  CAS  Google Scholar 

  47. Fukanoshi Y, Nakayama H, Uetsuka K, Nishimura R, Sasaki N, Doi K. Cellular proliferative and telomerase activtiy in canine mammary gland tumors. Vet Pathol 2000; 37: 177 - 183.

    Article  Google Scholar 

  48. Madewell BR, Gandour-Edwards R, Edwards BF, Walls JE, Griffey SM. Topographic distribution of bc1-2 protein in feline tissues in health and neoplasia. Vet Pathol 1999; 36: 565 - 573.

    Article  PubMed  CAS  Google Scholar 

  49. Madewell BR, Gandour-Edwards R, Edwards BF, Matthews KR, Griffey SM. Bax/bcl-2: cellular modulator of apoptosis in feline skin and basal cell tumours. J Comp Pathol 2001; 124: 115 - 121.

    Article  PubMed  CAS  Google Scholar 

  50. Phillips BS, Kass PH, Naydan DK, Winthrop MD, Griffey SM, Madewell BR. Apoptotic and proliferation indexes in canine lymphoma. J Vet Diagn Invest 1999; 12: 111 - 117.

    Article  Google Scholar 

  51. Roels S, Tilmant K, Ducatelle R. p53 expression and apoptosis in melanomas of dogs and cats. Res Vet Sci 2001; 70: 19 - 25.

    Article  PubMed  CAS  Google Scholar 

  52. Nicholls PK, Moore PF, Anderson DM, et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283: 31 - 39.

    Article  PubMed  CAS  Google Scholar 

  53. Dow SW, Elmslie RE, Wilson AP, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406 - 2414.

    Article  PubMed  CAS  Google Scholar 

  54. Korkolopoulou P, Oates J, Kittos C, Crocker J. p53, c-myc, p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin’s lymphomas. J Clin Pathol 1994; 47: 9 - 14.

    Google Scholar 

  55. Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000; 37: 54 - 61.

    Article  PubMed  CAS  Google Scholar 

  56. Mendoza S, Konishi T, Dernell WS, Withrow SJ, Miller CW. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 1998; 18: 4449 - 4453.

    PubMed  CAS  Google Scholar 

  57. Nambiar PR, Jackson ML, Ellis JA, Chelack BJ, Kidney BA, Haines DM. Immunohistochemical detection of tumor suppressor gene p53 protein in feline injection site-associated sarcomas. Vet Pathol 2001; 38: 236 - 238.

    Article  PubMed  CAS  Google Scholar 

  58. Nasir L, Rutteman GR, Reid SW, Schulze C, Argyle DJ. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Lett 2001; 174: 83 - 89.

    Article  PubMed  CAS  Google Scholar 

  59. Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N, Hayashi T. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 1999; 61: 27 - 32.

    Article  PubMed  CAS  Google Scholar 

  60. Veldhoen N, Stewart J, Brown R, Milner J. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998; 16: 249 - 255.

    Article  PubMed  CAS  Google Scholar 

  61. Veldhoen N, Watterson J, Brash M, Milner J. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer 1999; 81: 409 - 415.

    Article  PubMed  CAS  Google Scholar 

  62. Wakui S, Muto T, Yokoo K, et al. Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Res 2001; 21: 611 - 616.

    PubMed  CAS  Google Scholar 

  63. Griffey SM, Kraegel SA, Madewell BR. Rapid detection of K-ras gene mutations in canine lung cancer using single-strand conformational polymorphism analysis. Carcinogenesis 1998; 19: 959 - 963.

    Article  PubMed  CAS  Google Scholar 

  64. Merryman JI, Buckles EL, Bowers G, Neilsen NR. Overexpression of c-Ras in hyperplasia and adenomas of the feline thyroid gland: an immunohistochemical analysis of 34 cases. Vet Pathol 1999; 36: 117 - 124.

    Article  PubMed  CAS  Google Scholar 

  65. Watzinger F, Mayr B, Gamerith R, Vetter C, Lion T. Comparative analysis of ras proto-oncogene mutations in selected mammalian tumors. Mol Carcinog 2001; 30: 190 - 198.

    Article  PubMed  CAS  Google Scholar 

  66. Mayr B. Cytogenetic and tumour suppressor gene studies on feline soft tissue tumours. Vet Med Czech 2000; 45: 327 - 330.

    CAS  Google Scholar 

  67. Kolb E. Patho-biochemical aspects of the development of tumors in the dog. Tierarztliche Umschau 2001; 56: 128 - 134.

    Google Scholar 

  68. Nasir L, Devlin P, Mckevitt T, Rutteman G, Argyle DJ. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 2001; 3: 351 - 359.

    Article  PubMed  CAS  Google Scholar 

  69. Yazawa M, Okuda M, Setoguchi A, et al. Measurement of telomerase activity in dog tumors. J Vet Med Sci 1999; 61: 1125 - 1229.

    Article  PubMed  CAS  Google Scholar 

  70. Yazawa M, Okuda M, Setoguchi A, et al. Telomere length and telomerase activity in canine mammary gland tumors. Am J Vet Res 2001; 62: 1539 - 1543.

    Article  PubMed  CAS  Google Scholar 

  71. Lana SE, Ogilvie GK, Hansen RA, Powers BE, Dernell WS, Withrow SJ. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000; 61: 111 - 114.

    Article  PubMed  CAS  Google Scholar 

  72. Leibman NF, Lana SE, Hansen RA, et al. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med 2000; 14: 583 - 586.

    Article  PubMed  CAS  Google Scholar 

  73. Yokota H, Kumata T, Taketaba S, et al. High expression of 92 kDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochim Biophys Acta 2001; 1568: 7 - 12.

    Article  PubMed  CAS  Google Scholar 

  74. MacEwen EG, Kutzke J, Carew J, et al. C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 2003; 20: 421 - 430.

    Article  PubMed  CAS  Google Scholar 

  75. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor expression and function contribute to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2002; submitted.

    Google Scholar 

  76. Ferracini R, Angelini P, Cagliero E, et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 2000; 18: 253 - 256.

    Article  PubMed  CAS  Google Scholar 

  77. Matsuyama S, Nakamura M, Yonezawa K, et al. Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors. J Vet Med Sci 2001; 63: 949 - 954.

    Article  PubMed  CAS  Google Scholar 

  78. London CA, Kisseberth WC, Galli SJ, Geissler EN, Helfand SC. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumors. J Comp Pathol 1996; 115: 399 - 414.

    Article  PubMed  CAS  Google Scholar 

  79. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999; 112: 165 - 170.

    Article  PubMed  CAS  Google Scholar 

  80. Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L. Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 2000; 22: 49 - 54.

    Article  PubMed  CAS  Google Scholar 

  81. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002; 100: 585 - 593.

    Article  PubMed  CAS  Google Scholar 

  82. Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med 2000; 14: 479 - 485.

    Article  PubMed  CAS  Google Scholar 

  83. Clifford CA, Hughes D, Beal MW, et al. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med 2001; 15: 131 - 135.

    Article  PubMed  CAS  Google Scholar 

  84. Allen DK, Waters DJ, Knapp DJ, Kuczek T. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Intern Med 1996; 10: 231 - 234.

    Article  PubMed  CAS  Google Scholar 

  85. Wetterman C, Chun R, Winter B, Ross C. RT-PCR cloning and sequencing of vascular endothelial growth factor in canine osteosarcoma. Proc Vet Cancer Soc 1999; 19: 30.

    Google Scholar 

  86. Alexander AN, Huelsmeyer MK, Vail DM, Kurzman ID. Phase I/II clinical trial utilizing a tumor cell vaccine encoding xenogeneic gp 100 in canine patients with metastatic melanoma: immunological and clinical outcomes. In: Proceedings of the American Association Cancer Research, San Francisco, April 6 - 10, 2002.

    Google Scholar 

  87. Huelsmeyer MK, Alexander AN, Thamm DH, Vail DM, MacEwen EG. Development of a genetically modified allogeneic tumor cell vaccine targeting canine melanoma. In: Proceedings of the Americna Association Cancer Research, San Francisco, CA, April 6 - 10, 2002.

    Google Scholar 

  88. Crow SE. Lymphosarcoma in the dog: diagnosis and treatment. Comp Cont Ed Pract Vet 1982; 4: 283 - 289.

    Google Scholar 

  89. Leifer CE, Matus RE. Canine lymphoma: clinical considerations. Semin Vet Med Surg 1986; 1: 43 - 51.

    CAS  Google Scholar 

  90. Rosenthal RC. Epidemiology of canine lymphosarcoma. Comp Cont Ed Pract Vet 1982; 4: 855 - 859.

    Google Scholar 

  91. Owen LN, ed. World Health Organization TNM Classification ofTumors in Domestic Animals. Geneva,: WHO. 1980.

    Google Scholar 

  92. Anonymous. The non-Hodgkin’s lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 1982; 49: 2112.

    Google Scholar 

  93. Teske E, Rutteman GR, Kuipers-Dijkshoorn NJ, et, al. DNA ploidy and cell kinetics in canine non-Hodgkin’s lymphoma. Exp Hematol 1993; 21: 579 - 584.

    PubMed  CAS  Google Scholar 

  94. Carter RF, Valli VEO, Lumsden JH. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Can J Vet Res 1986; 50: 154 - 164.

    PubMed  CAS  Google Scholar 

  95. Greenlee PG, Fillipps DA, Quimby FW. Lymphomas in dogs. Cancer 1990; 66: 480 - 490.

    Article  PubMed  CAS  Google Scholar 

  96. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. JAm Vet Med Assoc 1994; 205: 1722 - 1728.

    CAS  Google Scholar 

  97. Hahn KA, Richardson RC, Hahn EA, Chrisman CL. Diagnostic and progostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Pathol 1994; 31: 528 - 540.

    Article  PubMed  CAS  Google Scholar 

  98. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993; 7: 289 - 295.

    Article  PubMed  CAS  Google Scholar 

  99. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study. JAm Hosp Assoc 2000; 36: 404 - 409.

    CAS  Google Scholar 

  100. Brons PPT, Raemaekers JMM, Bogman MJJT. Cell cycle kinetics in malignant lymphoma studied with in vivo iodeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry. Blood 1992; 80: 2336 - 2343.

    PubMed  CAS  Google Scholar 

  101. Mikou P, Kanavaros P, Aninos D. Nucleolar organizer regions (NORs) staining and proliferating cell nuclear antigen (PCNA) immunostaining in mucosa-associated lymphoid tissue (MALT) gastric lymphomas. Pathol Res Pract 1993; 189: 1004 - 1009.

    Article  PubMed  CAS  Google Scholar 

  102. Jakic-Razumovic J, Tentor D, Petrovecki M, Radman I. Nuclear organizer regions and survival in patients with non-Hodgkin’s lymphoma classified by the working formulation. J Clin Pathol 1993; 46: 943 - 947.

    Article  PubMed  CAS  Google Scholar 

  103. Crocker J, Nar P. Nucleolar organizer regions in lymphomas. J Pathol 1987; 151: 111 - 118.

    Article  PubMed  CAS  Google Scholar 

  104. Crocker J, McCartney JC, Smith PJ. Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin’s lymphomas. J Pathol 1988; 154: 151 - 156.

    Article  PubMed  CAS  Google Scholar 

  105. Gorczyca W, Kram A, Tuziak T. Proliferating cell nuclear antigen in archival surgical specimens of malignant lymphoma and metastatic carcinoma: immunohistochemical and flow cytometric analysis. Pathol Polska 1993; 44: 121 - 128.

    CAS  Google Scholar 

  106. Brick JO, Roenigk WJ, Wilson GP. Chemotherapy of malignant lymphoma in dogs and cats. JAm Vet Med Assoc 1968; 153: 47 - 52.

    CAS  Google Scholar 

  107. Vail DM. Recent advances in chemotherapy for lymphoma of dogs and cats. Comp Cont Ed Pract Vet 1993; 15: 1031 - 1037.

    Google Scholar 

  108. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a six-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16: 704 - 709.

    Article  PubMed  Google Scholar 

  109. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996; 10: 354 - 359.

    Article  PubMed  CAS  Google Scholar 

  110. Lee JJ, Hughes CS, Fine RL, Page RL. P-glycoprotein expression in canine lymphoma. Cancer 1986; 77: 1892 - 1898.

    Article  Google Scholar 

  111. Steingold SF, Sharp NJ, McGahan MC, Hughes CS, Dunn SE, Page RL. Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer Res 1998; 18: 393 - 400.

    CAS  Google Scholar 

  112. Gamblin RM, Sagartz JE, Couto CG. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997; 58: 857 - 863.

    PubMed  CAS  Google Scholar 

  113. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39: 410 - 416.

    Article  PubMed  CAS  Google Scholar 

  114. Thamm DH, MacEwen EG, Phillips BS, et al. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother Pharmacol 2002; 49: 251 - 255.

    Article  PubMed  CAS  Google Scholar 

  115. Page RL, Macy DW, Ogilvie GK. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. Int J Hyperthermia 1992; 8: 187 - 197.

    Article  PubMed  CAS  Google Scholar 

  116. Applebaum FR, Deeg HJ, Storb R. Marrow transplant studies in dogs with malignant lymphoma. Transplantation 1985; 39: 499 - 504.

    Article  Google Scholar 

  117. Weiden PL, Storb R, Deeg HJ, et al. Prolonged disease-free interval in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapyinduced remissions. Blood 1979; 54: 1039 - 1049.

    PubMed  CAS  Google Scholar 

  118. Hardy Jr WD. The feline leukemia virus. J Am Anim Hosp Assoc 1981; 17: 951 - 957.

    Google Scholar 

  119. Hardy Jr WD, Zuckerman EE, MacEwen EG, et al. A feline leukemia and sarcoma virus-induced tumor specific antigen. Nature 1977; 270: 249 - 251.

    Article  PubMed  Google Scholar 

  120. Cockerell GL, Krakowa S, Hoover EA. Characterization of feline T- and B-lymphocytes and identification of an experimentally induced T-cell neoplasm in the cat. JNatl Cancer Inst 1976; 57: 907 - 913.

    CAS  Google Scholar 

  121. Hardy Jr WD, McClelland AJ, Zuckerman EE, et al. Development of virus nonproducer lymphosarcomas in pet cats exposed to FeLV. Nature 1980; 288: 90 - 92.

    Google Scholar 

  122. Rojko JL, Kociba GJ, Abkowitz JL, et al. Feline lymphomas: immunological and cytochemical characterization. Cancer Res 1989; 49: 345 - 351.

    PubMed  CAS  Google Scholar 

  123. Vail DM, Moore AS, Ogilvie GK, Volk LM. Feline lymphoma (145 cases): proliferation indices, CD3 immunoreactivity, and their associateion with prognosis in 90 cats. J Vet Intern Med 1998; 12: 349 - 354.

    Article  PubMed  CAS  Google Scholar 

  124. Mauldin GE, Mooney SC, Meleo KA, et al. Chemotherapy in 132 cats with lymphoma: 1988-1994. In: Proceedings of the 15th Annual Conference of Veterinary Cancer Society,Tuscon, AZ, 1995. Vol. 15.

    Google Scholar 

  125. Poli A, Abramo F, Baldinotti F, Pistello M, Da Prato L, Bendinelli M. Malignant lymphoma associated with experimentally induced feline immunodeficiency virus infection. J Comp Pathol 1994; 1 10: 319 - 328.

    Article  Google Scholar 

  126. Shelton GH, Grant CK, Cotter SM, Gardner MB, Hardy WD Jr, DiGiacomo RF. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: a retrospective study (1968-1988). JAcquirlmmunodef Syndr 1990; 3: 623 - 630.

    CAS  Google Scholar 

  127. Valli VE, Jacobs RM, Norris A, et al. The histologic classification of 602 cases of feline lymphoproliferative disease using the National Cancer Institute working formulation. J Vet Diagn Invest 2000; 12: 295 - 306.

    Article  PubMed  CAS  Google Scholar 

  128. Hardy WD Jr. Hematopoietic tumors of cats. JAm Anim Hosp Assoc 1981; 17: 921 - 940.

    Google Scholar 

  129. Mooney SC, Hayes AA, MacEwen EG, Matus RE, Geary A, Shurgot BA. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). JAm Vet Med Assoc 1989; 194: 696 - 702.

    CAS  Google Scholar 

  130. Theilen GH, Madewell BR. Tumors of the skin and subcutaneous tissues. In: Theilen GN, Madewell BR, eds. Veterinary Cancer Medicine. Philadelphia: Lea Febinger, 1979: 123 - 191.

    Google Scholar 

  131. McNiel EA. Vaccine-associated sarcomas in cats: a unique cancer model. Clin Orthop 2001; 382: 21 - 27.

    Article  PubMed  Google Scholar 

  132. Hendrick MJ, Goldschmidt MH, Shofer FS, Wang YY, Somlyo AP. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 1992; 52: 5391 - 5394.

    PubMed  CAS  Google Scholar 

  133. Hendrick MJ, Kass PH, McGill LD, Tizard IR. Postvaccinal sarcomas in cats. J Natl Cancer Inst 1994; 86: 341 - 343.

    Article  PubMed  CAS  Google Scholar 

  134. Kass PH, Barnes WGJ, Spangler WL, Chomel BB, Culbertson MR. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. JAm Vet Med Assoc 1993; 203: 396 - 405.

    CAS  Google Scholar 

  135. Hardy WD Jr. The etiology of canine and feline tumors. JAm Anim Hosp Assoc 1976; 12: 313 - 334.

    Google Scholar 

  136. Madewell BR, Theilen GN. Etiology of cancer in animals. In: Theilen GN, Madewell BR, eds. Veterinary Cancer Medicine. Philadelphia: Lea Febinger. 1979: 13 - 25.

    Google Scholar 

  137. McEntee MC, Page RL. Feline vaccine-associated sarcomas. J Vet Intern Med 2001; 15: 176 - 182.

    Article  PubMed  CAS  Google Scholar 

  138. Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc 1997; 211: 1147 - 1151.

    PubMed  CAS  Google Scholar 

  139. Cohen M, Wright JC, Brawner WR, Smith AN, Henderson R, Behrend EN. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). JAm Vet Med Assoc 2001; 219: 1582 - 1589.

    Article  CAS  Google Scholar 

  140. Atwater SW, LaRue SW, Powers BE, Withrow SJ. Adjuvant radiotherapy of soft-tissue sarcomas in dogs. In: Proceedings of the 12thAnnual Conference of the Veterinary Cancer Society, Pacific Grove, CA, Oct 18 - 21, 1992.

    Google Scholar 

  141. McKnight JA, Mauldin GN, McEntee MC, Meleo KA, Patnaik AK. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. JAm Vet Med Assoc 2000; 17: 205 - 210.

    Article  Google Scholar 

  142. Forrest LJ, Chun R, Adams WM, Cooley AJ, Vail DM. Postoperative radiotherapy for canine soft tissue sarcoma. J Vet Intern Med 2000; 14: 578 - 582.

    Article  PubMed  CAS  Google Scholar 

  143. Prescott DM, Charles HC, Sostman HD, et al. Manipulation of intra-and extracellular pH in spontaneous canine tumors by use of hyperglycemia. Int J Hyperthermia 1993; 9: 745 - 754.

    Article  PubMed  CAS  Google Scholar 

  144. Prescott DM, Samulski TV, Dewhirst MW, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992; 23: 377 - 385.

    Article  PubMed  CAS  Google Scholar 

  145. Thrall DE, Dewhirst MW, Page RL, et al. A comparison of temperatures in canine solid tumors during local and whole-body hyperthermia administered alone and simultaneously. IntJHyperthermia 1990; 6: 305 - 317.

    Google Scholar 

  146. Dewhirst MW, Prescott DM, Clegg S, et al. The use of hydralazine to manipulate tumor temperatures during hyperthermia. Int J Hyperthermia 1990; 6: 971 - 983.

    Article  PubMed  CAS  Google Scholar 

  147. Gillette SM, Dewhirst MW, Gillette EL, et al. Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study. Int J Hyperthermia 1992; 8: 309 - 329.

    Article  PubMed  CAS  Google Scholar 

  148. Page RL, Thrall DE, George SL, et al. Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumor-bearing dogs. Int J Hyperthermia 1992; 8: 761 - 769.

    Article  PubMed  CAS  Google Scholar 

  149. Sostman HD, Prescott DM, Dewhirst MW, et al. MR imaging and spectroscopy for prognostic evaluation in soft-tissue sarcomas. Radiology 1994; 190: 269 - 275.

    PubMed  CAS  Google Scholar 

  150. Prescott DM, Charles HC, Sostman HD, et al. Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int J Radiat Oncol Biol Phys 1994; 28: 415 - 423.

    Article  PubMed  CAS  Google Scholar 

  151. Oksanen A. Hemangiosarcoma in dogs. J Comp Pathol 1978; 88: 585 - 595.

    Article  PubMed  CAS  Google Scholar 

  152. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. JAm Vet Med Assoc 1985; 186: 56 - 58.

    CAS  Google Scholar 

  153. Kline Li, Zook BC, Munson TO. Primary cardiac hemangiosarcoma in dogs. JAm Vet Med Assoc 1970; 157: 326 - 337.

    Google Scholar 

  154. Spangler WL, Culbertson MR. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). JAm Vet Med Assoc 1992; 200: 829 - 834.

    CAS  Google Scholar 

  155. Nikula KJ, Benjamin SA, Angleton GM, Saunders WJ, Lee AC. Ultraviolet radiation, solar dermatosis, and cutaneous neoplasia in beagle dogs. Radiat Res 1992; 129: 11 - 18.

    Article  PubMed  CAS  Google Scholar 

  156. Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs. J Vet Intern Med 1989; 3: 160 - 166.

    Article  PubMed  CAS  Google Scholar 

  157. Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991; 5: 160 - 166.

    Article  PubMed  CAS  Google Scholar 

  158. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine splenic hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993; 7: 370 - 376.

    Article  PubMed  CAS  Google Scholar 

  159. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995; 1: 1165 - 1170.

    PubMed  CAS  Google Scholar 

  160. Fidler IJ. Macrophages and metastasis-a biological approach to cancer therapy. Cancer Res 1985; 45: 4714 - 4726.

    PubMed  CAS  Google Scholar 

  161. Kleinerman ES, Fidler IJ. Systemic activation of macrophages by liposomes containing immunomodulators. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott. 1995: 829 - 839.

    Google Scholar 

  162. Inadomi T, Fujioka A, Suzuki H. A case of malignant hemangioendothelioma showing response to interkeukin-2 therapy. Br J Dermatol 1992; 127: 442 - 449.

    Article  PubMed  CAS  Google Scholar 

  163. Hershey AE, Kurzman ID, Moore AS, et al. Efficacy of combined inhalational doxorubicin and systemic doxorubicin/cytoxan for adjuvant treatment of canine splenic hemangiosarcoma. In: Proceedings of the 18th Annual ACVIM Forum, Seattle, WA, 2000.

    Google Scholar 

  164. Sorenmo K, Duda L, Barber L, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000; 14: 395 - 398.

    Article  PubMed  CAS  Google Scholar 

  165. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general information and a review of canine skeletal osteosarcoma. Yale J Biol Med 1979; 52: 345 - 361.

    Google Scholar 

  166. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Clin Orthop 1991; 270: 159 - 168.

    PubMed  Google Scholar 

  167. Vail DM, Kurzman ID, Glawe PC, et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50: 131 - 136.

    Article  PubMed  CAS  Google Scholar 

  168. Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000; 14: 587 - 592.

    Article  PubMed  CAS  Google Scholar 

  169. Ehrhart N, Dernell WS, Hoffmann WE, Weigel RM, Powers BE, Withrow SJ. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (19901996). JAm Vet Med Assoc 1998; 213: 1002 - 1006.

    CAS  Google Scholar 

  170. Spodnick GJ, Berg RJ, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). JAm Vet Med Assoc 1992; 200: 995 - 999.

    CAS  Google Scholar 

  171. Brodey RS, Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. JAm Vet Med Assoc 1976; 168: 1032 - 1035.

    CAS  Google Scholar 

  172. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. JAm Vet Med Assoc 1995; 206: 1555 - 1560.

    CAS  Google Scholar 

  173. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). J Vet Intern Med 1995; 10: 76 - 81.

    Article  Google Scholar 

  174. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991; 5: 205 - 210.

    Article  PubMed  CAS  Google Scholar 

  175. MacEwen EG, Kurzman ID, Rosenthal RC, et al. MLV-MTP-PE with cisplatin in canine osteosarcoma model. A randomized trial. In: Novak JF, MacMaster JH, eds. Frontiers in Osteosarcoma Research. Toronto: Hogrefer and Huber. 1993: 117 - 119.

    Google Scholar 

  176. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. JNatl Cancer Inst 1989; 81: 935 - 938.

    Article  CAS  Google Scholar 

  177. MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A Lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target 1994; 2: 391 - 396.

    Article  PubMed  CAS  Google Scholar 

  178. Kurzman ID, MacEwen EG, Rosenthal RC. Therapy for osteosarcoma in dogs with combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995; 1: 1595 - 1601.

    PubMed  CAS  Google Scholar 

  179. Straw RC, Withrow SJ, Brekke JH, et, al. The effects of cis-diammine-dichloroplatinum II released from D,L-polylactic acid implants adjacent to cortical allografts in dogs. J Orthop Res 1994; 12: 871 - 877.

    Article  PubMed  CAS  Google Scholar 

  180. Sliverberg E, Lubera J. Cancer statistics. CA 1987; 37: 2 - 19.

    Google Scholar 

  181. Schneider R, Dorn CR, Taylor DON. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969; 43: 1249 - 1261.

    PubMed  CAS  Google Scholar 

  182. Sorenmo KU, Shofer FS, Goldschmidt MH. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med 2000; 14: 266 - 270.

    Article  PubMed  CAS  Google Scholar 

  183. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM, Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 2000; 37: 239 - 247.

    Article  PubMed  CAS  Google Scholar 

  184. Sartin EA, Barnes S, Kwapien RP, et al. Estrogen and progesterone receptor status of mammary carcinomas and correlation with clinical outcome. Am J Vet Res 1992; 53: 2196 - 2200.

    PubMed  CAS  Google Scholar 

  185. Rutteman GR, Misdorp W, Blankenstein MA, et al. Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in malignant and nonmalignant states. Br J Cancer 1988; 58: 594 - 599.

    Article  PubMed  CAS  Google Scholar 

  186. MacEwen EG, Patnaik AK, Harvey HJ, et al. Estrogen receptors in canine mammary tumors. Cancer Res 1982; 42: 2255 - 2259.

    PubMed  CAS  Google Scholar 

  187. Martin PM, Cotard M, Mialot JP, et al. Animal models for hormone-dependent human breast cancer. Cancer Chemother Pharmacol 1984; 2: 13 - 17.

    Google Scholar 

  188. Morris JS, Dobson JM, Bostock DE. Use of tamoxifen in the control of mammary neoplasia. Vet Rec 1993; 133: 539 - 542.

    Article  PubMed  CAS  Google Scholar 

  189. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983; 20: 127 - 142.

    PubMed  CAS  Google Scholar 

  190. Misdorp W, Cotchin E, Hampe JF, Jabara AG, von Sandersleben J. Canine malignant mammary tumours. I. Sarcomas. Vet Pathol 1971; 8: 99 - 117.

    PubMed  CAS  Google Scholar 

  191. Misdorp W, Cotchin E, Hampe JF, et, al. Canine malignant mammary tumors. II. Adenocarcinomas, solid carcinomas, and spindle cell carcinomas. Vet Pathol 1972; 9: 447 - 470.

    Google Scholar 

  192. Misdorp W, Cotchin E, Hampe JF, Jabara AG, von Sandersleben J. Canine malignant mammary tumors. III. Special types of carcinomas, malignant mixed tumors. Vet Pathol 1973; 10: 241 - 256.

    Article  PubMed  CAS  Google Scholar 

  193. Hellmen E, Moller M, Blankenstein MA, Andersson L, Westermark B. Expression of different phenotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Res Treat 2000; 61: 197 - 210.

    Article  PubMed  CAS  Google Scholar 

  194. Silver SA, Tavassoli FA. Primary osteogenic sarcoma of the breast: a clinicopathologic analysis of 50 cases. Am J Surg Pathol 1998; 22: 925 - 933.

    Article  PubMed  CAS  Google Scholar 

  195. Kurzman ID, Gilbertson SR. Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1986; 1: 25 - 32.

    CAS  Google Scholar 

  196. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 1993; 30: 20 - 27.

    Article  PubMed  CAS  Google Scholar 

  197. MacEwen EG, Harvey HJ, Patnaik AK, et al. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol Response Mod 1985; 4: 418 - 426.

    PubMed  CAS  Google Scholar 

  198. Parodi AL, Misdorp W, Mialot JP, et al. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 1983; 15: 172 - 177.

    Article  PubMed  CAS  Google Scholar 

  199. Bostock DE, Gorman NT. Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour. Eur J Cancer 1978; 14: 8789 - 883.

    Google Scholar 

  200. Hayes HMJ, Milne K, Mandell CP. Epidemiological features of feline mammary carcinoma. Vet Rec 1981; 108: 476 - 479.

    Article  PubMed  Google Scholar 

  201. Elling H, Ungemach FR. Progesterone receptors in feline mammary cancer cytosol. J Cancer Res Clin Oncol 1981; 100: 325 - 327.

    Article  PubMed  CAS  Google Scholar 

  202. Johnston SD, Hayden DW, Kiang DT, Handschin B, Johnson KH. Progesterone receptors in feline mammary adenocarcinomas. Am J Vet Res 1984; 45: 397 - 382.

    Google Scholar 

  203. Rutteman GR, Blankenstein MA, Minke J, Misdorp W. Steroid receptors in mammary tumours of the cat. Acta Endocrinol (Copenh) 1991; 125 (suppl): 32 - 37.

    CAS  Google Scholar 

  204. Weijer K, Hart AA. Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983; 70: 709 - 716.

    PubMed  CAS  Google Scholar 

  205. MacEwen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S. Prognostic factors for feline mammary tumors. JAm Vet Med Assoc 1984; 185: 201 - 204.

    CAS  Google Scholar 

  206. Jeglum K, A, deGuzman E, Young KM. Chemotherapy of advanced mammary adenocarcinoma in 14 cats. JAm Vet Med Assoc 1985; 187: 157 - 1650.

    CAS  Google Scholar 

  207. Mauldin G, Matus R, Patnaik A. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988; 2: 60 - 65.

    Article  PubMed  CAS  Google Scholar 

  208. MacEwen EG, Hayes AA, Mooney S, et al. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response Mod 1984; 3: 541 - 546.

    PubMed  CAS  Google Scholar 

  209. Rutten VP, Misdorp W, Gauthier A, et al. Immunological aspects of mammary tumors in dogs and cats: a survey including own studies and pertinent literature. Vet Immunol Immunopathol 1990; 26: 211 - 225.

    Article  PubMed  CAS  Google Scholar 

  210. Fox LE, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double-blind study. Cancer Biother 1995; 10: 125 - 130.

    Article  PubMed  CAS  Google Scholar 

  211. Hoyt RF, Withrow SJ. Oral malignancy in the dog. JAm An Hosp Assoc 1982; 20: 83 - 92.

    Google Scholar 

  212. Harvey HJ, MacEwen EG, Braun D, Patnaik AK, Withrow SJ, Jongeward S. Prognostic criteria for dogs with oral melanoma. JAm Vet Med Assoc 1981; 178: 580 - 582.

    CAS  Google Scholar 

  213. MacEwen EG, Patnaik AK, Harvey HJ, Hayes AA, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 1986; 4: 397 - 402.

    Article  PubMed  CAS  Google Scholar 

  214. Page RL, Thrall DE, Dewhirst MW, et, al. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. Int J Hyperthermia 1991; 7: 559 - 566.

    Article  PubMed  CAS  Google Scholar 

  215. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). JAm Vet Med Assoc 2001; 218: 1444 - 1448.

    Article  CAS  Google Scholar 

  216. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996; 209: 98 - 102.

    PubMed  CAS  Google Scholar 

  217. Bateman KE, Catton PA, Pennock PM, Kruth SA. 0-7-21 radiation therapy for the palliation of advanced cancer in dogs. J Vet Intern Med 1994; 8: 394 399.

    Google Scholar 

  218. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 2003; 44: 352 - 359.

    Article  PubMed  Google Scholar 

  219. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and GM-CSF. Clin Cancer Res 1999; 5: 4249 - 4258.

    PubMed  CAS  Google Scholar 

  220. Hogge GS, Burkholder JK, Culp J, et al. Development of hGM-CSF transfected tumor cell vaccines in spontaneous canine cancer. Human Gene Ther 1998; 9: 1851 - 1861.

    Article  CAS  Google Scholar 

  221. Walsh P, Gonzalez R, Dow S, et al. A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial. Hum Gene Ther 2000; 11: 1355 - 1368.

    Article  PubMed  CAS  Google Scholar 

  222. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder: a relevant model of human invasive bladder cancer. Urol Oncol 2000; 5: 47 - 59.

    Article  PubMed  CAS  Google Scholar 

  223. Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am An Hosp Assoc 1994; 30: 270 - 275.

    Google Scholar 

  224. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996; 209: 1588 - 1591.

    PubMed  CAS  Google Scholar 

  225. Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional call carcinoma of the urinary bladder or urethra: a retrospective study of 15 dogs. J Vet Intern Med 1990; 4: 148 - 152.

    Article  PubMed  CAS  Google Scholar 

  226. Marynissen JP, Jansen H, Star WM. Treatment system for whole bladder wall photodynamic therapy with in vivo monitoring and control of light dose rate and dose. J Urol 1989; 142: 1351 - 1355.

    PubMed  CAS  Google Scholar 

  227. Nseyo UO, Dougherty TJ, Boyle DG, Potter WR. Study of factors mediating effect of photodynamic therapy on bladder in canine bladder model. Urology 1988; 32: 41 - 45.

    Article  PubMed  CAS  Google Scholar 

  228. Nseyo UO, Whalen RK, Lundahl SL. Canine bladder response to red and green light whole bladder photodynamic therapy. Urology 1993; 41: 392 - 396.

    Article  PubMed  CAS  Google Scholar 

  229. Knapp DW,. Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994; 8: 273 - 278.

    Google Scholar 

  230. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000; 46: 221 - 226.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. David M. Vail DVM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas H. Thamm VMD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Discovery and Research, Genzyme Corporation, Framingham, MA, USA

    Beverly A. Teicher PhD (Vice President and Director of Oncology Portfolio) (Vice President and Director of Oncology Portfolio)

  2. Preclinical Sciences, Aton Pharma Inc., Tarrytown, NY, USA

    Paul A. Andrews PhD (Senior Director) (Senior Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Vail, D.M., Thamm, D.H. (2004). Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development. In: Teicher, B.A., Andrews, P.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-739-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-739-0_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9841-7

  • Online ISBN: 978-1-59259-739-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation